linear gradient of 1% B to 95% B over 60 min was used with detection at 210 nm and 254 nm. Semipreparative RP-HPLC was performed on a Dionex Ultimate 3000 System using a semi-preparative column (Phenomenex Gemini C 18 , 110 Å, 250 mm x 10 mm, 5 μm) at a flow rate of 5 mL min -1 using a linear gradient of 5% B to 95% B over 95 min with detection at 210 nm. Nuclear magnetic resonance spectra were recorded on a Bruker AVANCE 400 spectrometer ( 1 H 400 MHz; 13 C 100 MHz) using a Norell ® (5.0 mm) NMR tube for CPI-2081a (1) and a Wilmad ® (3.0 mm) NMR tube for CPI-2081b (2) . NMR spectra were carried out using (CD 3 ) 2 SO as the solvent which was also used to calibrate the spectrum at 2.50 ppm in the 1 H NMR and 39.5 ppm in the 13 C NMR. Infrared spectra were recorded from the dry form (evaporated from a mixture of CH 2 Cl 2 :MeOH 9:1) on a Perkin Elmer Spectrum 100 infrared spectrometer and reported in wavenumbers ( , cm -1 ). Optical rotations were determined at the sodium D line (589 nm) at 20 °C on a Perkin Elmer 341 polarimeter and are given in units of 10 -1 deg cm 2 g -1 . LCMS spectra were acquired on an Agilent Technologies 1120
Compact LC equipped with a Hewlett Packard 1100 MSD mass spectrometer using an analytical column (Phenomenex Jupiter C 18 , 300 Å, 150 mm x 4.6 mm, 5 μm) at a flow rate of 0.3 mL min -1 using a linear gradient of 5% B (0.1% TFA/MeCN (v/v)) to 95% B over 60 min.
All reagents were purchased as reagent grade and used without further purification; solvents were also used without further purification. N,N-Dimethylformamide and acetonitrile was purchased from Scharlau. Triflouroacetic acid was purchased from Oakwood Products Inc. N,Ndiisopropylethylamine, piperidine and acetic anhydride were purchased from Sigma-Aldrich. Formic acid was purchased from Fluka Analytical as MS grade. HBTU, Fmoc-Phe-Wang preloaded on polystyrene resin, Fmoc-L-Leu-OH, Fmoc-L-Cys(tBu)-OH, and Fmoc-L-Ala-OH were purchased from GL Biochem (Shanghai) Ltd. Fmoc-L-Trp-OH (indole unprotected) was purchased from Peptides International.
Procedure for Peptide Synthesis
Peptides were synthesized on a 0.1 mmol scale by manual Fmoc-SPPS. Portions of resin were exposed to different cleavage conditions to afford crude mixtures of the two peptides CPI-2081a (1) and CPI-2081b (2) which were then purified by RP-HPLC or by silica flash column chromatography.
Manual Fmoc SPPS
Fmoc-Phe-Wang preloaded (0.72 mmol g -1 ) on polystyrene resin (139 mg, 0.1 mmol) was swollen in CH 2 Cl 2 (15 min) and then the resin was washed with DMF (2 x 5 mL). The Fmoc group was removed with 20% piperidine in DMF (1 x 5 min, 1 x 15 min) after which the resin was washed with DMF (3 x 5 mL). A mixture of Fmoc-L-Ala-OH (4.0 eq, 124 mg) and HBTU (3.9 eq, 148 mg) was added to the resin followed by the addition of DIPEA (8.0 eq, 140 μL). The mixture was agitated for 40 min after which the supernatant was drained from the resin which was then washed with DMF (3 x 5 mL) and coupling confirmed by negative Kaiser test. The Fmoc group was removed with 20% piperidine in DMF (1 x 5 min, 1 x 15 min) after which the resin was washed with DMF (3 x 5 mL). A mixture of Fmoc-L-Trp-OH (4.0 eq, 170 mg) and HBTU (3.9 eq, 148 mg) was added to the resin followed by the addition of DIPEA (8.0 eq, 140 μL). The mixture was agitated for 40 min after which the supernatant was drained from the resin which was then washed with DMF (3 x 5 mL) and coupling confirmed by negative Kaiser test. The Fmoc group was deprotected with 20% piperidine in DMF (1 x 5 min, 1 x 15 min) after which the resin was washed with DMF (3 x 5 mL). A mixture of Fmoc-L-Cys(tBu)-OH (4.0 eq, 160 mg) and HBTU (3.9 eq, 148 mg) was added to the resin followed by the addition of DIPEA (8.0 eq, 140 μL). The mixture was agitated for 40 min after which the supernatant was drained from the resin which was then washed with DMF (3 x 5 mL) and coupling confirmed by negative Kaiser test. The Fmoc group was removed with 20% piperidine in DMF (1 x 5 min, 1 x 15 min) after which the resin was washed with DMF (3 x 5 mL). A mixture of Fmoc-L-Leu-OH (4.0 eq, 145 mg) and HBTU (3.9 eq, 148 mg) was added to the resin followed by the addition of DIPEA (8.0 eq, 140 μL). The mixture was agitated for 40 min after which the supernatant was drained from the resin which was then washed with DMF (3 x 5 mL) and coupling confirmed by negative Kaiser test. A mixture of acetic anhydride (10 eq, 98 μL) and DIPEA (10 eq, 160 μL) in DMF (3 mL) was then added to the resin and the reaction agitated for 30 min after which the supernatant was drained from the resin which was washed with DMF (3 x 5 mL). N-terminal capping was confirmed by negative Kaiser test.
Cleavage
The resin containing the assembled peptide sequence, (Ac-Leu-Cys(tBu)-Trp-Ala-Phe-OH) was divided into two portions. To obtain CPI-2081a (1), the peptide was cleaved from the linker by gently agitating the resin-bound peptide with a "standard scavenging" mixture of TFA:TIS:H 2 O:2,2'-(ethylenedioxy)diethanethiol (94:1:2.5:2.5, 4 mL) for 3 h. The supernatant containing the crude peptide was isolated from the resin by filtration and the resin further washed with neat TFA (2 x 1 mL). As the crude linear peptide was soluble in cold Et 2 O, the TFA filtrate mixture was diluted with H 2 O and MeCN (1:1, 40 mL) and lyophilized to dryness. To obtain CPI-2081b (2), the peptide was cleaved from the linker by gently agitating the resin-bound peptide with neat TFA under a variety of conditions ( Table 1 ). The supernatant containing the crude peptide was isolated from the resin by filtration and the resin further washed with neat TFA (2 x 1 mL). As the crude linear peptide was soluble in cold Et 2 O, the TFA filtrate mixture was diluted with H 2 O and MeCN (1:1, 40 mL) and lyophilized to dryness.
Purification
When synthesised by the above procedure, using scavengers during cleavage to prevent the formation of CPI-2081b (2), CPI-2081a (1) was easily purified using reverse phase HPLC. The crude peptide (20 mg) was dissolved in DMSO (1 mL) and loaded onto a semi-preparative column (Phenomenex Gemini C 18 , 110 Å, 250 mm x 10 mm, 5 μm) equilibriated to 5% B, at a flow rate of 5 mL min -1 . The peptide was eluted using a linear gradient of 1% B per minute and the fractions collected at 46 min contained pure CPI-2081a (1) as determined by analytical HPLC and MS analysis. CPI-2081b (2) was more difficult to purify. Although enriched to 65% CPI-2081b (2), the reaction mixture always contained approximately 35% of the closely eluting CPI-2081a (1) . Sufficiently pure samples of CPI2081b (2) could not be obtained by reverse phase HPLC purification methods due to co-elution. To this end, CPI-2081b (2) was purified by column chromatography on normal phase silica gel using a solvent of 7% MeOH in CH 2 Cl 2 (0.5 % AcOH), Rf CPI-2081a (1) 
